CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Post-progression off-label Trastuzumab treatment of HER2 amplified metastatic gastric cancer – Case study
DOI 10.1055/s-0032-1312422
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Sahin, L Tóth, K Böszörményi, Z Nagy, Z Zaka, R Schwab, I Peták, F Oduncu, M Dank, L Topa
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe05/2012
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: A change in the HER2 gene copy number can be detected at 16–20% cent of gastric cancer patients. ToGA trial proved that chemotherapy combined with targeted HER-2 antibodies improved survival of this group by 20%, which prompted a registration of Trastuzumab as the first-line treatment of this patient group; its administration is indicated until the onset of progression. Our Patient: In our 72-year-old ma…
Zitieren
Zitierempfehlung
P Sahin, L Tóth, K Böszörményi, Z Nagy, Z Zaka, R Schwab, I Peták, F Oduncu, M Dank, L Topa (2012) Post-progression off-label Trastuzumab treatment of HER2 amplified metastatic gastric cancer – Case study. Zeitschrift für Gastroenterologie (05). https://doi.org/10.1055/s-0032-1312422
Mit CareLit weiterarbeiten